Key Drivers
- Strong Liquidity
- Ongoing Cash Burn
- Weak Solvency
AIAI Summary
GH has shifted from a “future promise” to a commercially validated growth story with real traction in FDA approvals, guideline inclusion, and strong revenue/test-volume growth, but investors should only lean in if management can convert that demand into operating leverage fast enough to offset ongoing cash burn and negative equity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Ongoing Cash Burn
- •Weak Solvency
GH remains a liquidity-supported but fundamentally challenged business, with strong cash reserves and gross margins offset by persistent operating losses, negative free cash flow, and a weakening balance sheet.
Price Behavior
Key Price Behavior Insights:
- •Failed breakout
- •Nearby support
- •Reversal risk
GH has shown a constructive rebound over the last month but remains short-term cautious after failing to hold the $165-$168 breakout, with support at $155-$157 and downside risk toward $150 and $144-$145 if that zone breaks.
Sharp rally from $148.07 to $168.48 was followed by a quick reversal, suggesting overextension and profit-taking
Sentiment & News
Key News Insights:
- •Revenue Beat
- •Guidance Raise
- •Insider Pressure
Guardant Health delivered strong Q2 revenue growth and lifted 2026 guidance, but sentiment remains mixed as shares slipped and insider/fund activity added caution.
The outlook is constructive on fundamentals, but near-term share performance may stay volatile until investor sentiment improves
Similar Companies in Healthcare
Other companies in the same sector with AI ratings